Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

about

Oncogenic role of miR‑183‑5p in lung adenocarcinoma: A comprehensive study of qPCR, in vitro experiments and bioinformatic analysis.ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.

P2860

Q54089180-F8215EA0-9B83-491C-B446-4AB26FDF5A12 Q54112592-5B51130A-8BDE-4926-82F5-39E95C3403E7

P2860

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

Item

http://www.wikidata.org/entity/Q39458295

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@en

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@nl

type

Item

label

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@en

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@nl

prefLabel

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@en

Spotlight on ramucirumab in th ...... opment, and clinical activity.

@nl

P1476

Spotlight on ramucirumab in th ...... lopment, and clinical activity

@en

P2093

Inmaculada Ramos

http://www.w3.org/2001/XMLSchema#string

Irene López

http://www.w3.org/2001/XMLSchema#string

Jose Manuel Trigo

http://www.w3.org/2001/XMLSchema#string

Macarena Arroyo

http://www.w3.org/2001/XMLSchema#string

Manuel Cobo

http://www.w3.org/2001/XMLSchema#string

María Ruiz

http://www.w3.org/2001/XMLSchema#string

Omar López

http://www.w3.org/2001/XMLSchema#string

Rosa Villatoro

http://www.w3.org/2001/XMLSchema#string

Vanesa Gutiérrez

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

The structural basis for the function of two anti-VEGF receptor 2 antibodies

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Angiogenesis: an organizing principle for drug discovery?

Angiogenesis as a therapeutic target

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

P304

57-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/LCTT.S118996

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ana Godoy

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744168

http://www.w3.org/2001/XMLSchema#string

P932

5513829

http://www.w3.org/2001/XMLSchema#string

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

about

P2860

P2860

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932